Bender Robert & Associates Biogen Inc. Transaction History

Bender Robert & Associates

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 30, 2019	SELL	$219.29 - $241.72 $2.05 Million - $2.26 Million	-9,342 Closed	0 $0
Q1 2019 Apr 30, 2019	SELL	$216.71 - $338.96 $97,519 - $152,532	-450 Reduced 4.6%	9,342 $2.21 Million
Q4 2018 Jan 24, 2019	SELL	$278.5 - $352.75 $20,052 - $25,398	-72 Reduced 0.73%	9,792 $2.95 Million
Q2 2018 Jul 27, 2018	BUY	$257.52 - $306.91 $7,983 - $9,514	31 Added 0.32%	9,864 $2.86 Million
Q1 2018 Apr 27, 2018	BUY	$260.13 - $367.91 $90,785 - $128,400	349 Added 3.68%	9,833 $2.69 Million
Q4 2017 Jan 19, 2018	SELL	$307.64 - $344.58 $35,993 - $40,315	-117 Reduced 1.22%	9,484 $3.02 Million
Q3 2017 Oct 23, 2017	BUY	$281.15 - $329.69 $2.7 Million - $3.17 Million	9,601	9,601 $3.01 Million

1,049

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $26.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Bender Robert & Associates, based on Form 13F filings with the SEC.

Stay updated on Bender Robert & Associates with notifications on news.